Effects of losartan on the sexual behavior of male rats

Paul Chan, Ju Chi Liu, Yat Ching Tong, Yi Jen Chen, Chia Chen Wang, Brian Tomlinson, Juei Tang Cheng

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Many commonly used antihypertensive drugs such as diuretics and beta-blockers can interfere with sexual function in both sexes, causing loss of libido, impairment of erectile function and ejaculation in men, and delay or prevent orgasm in women. Newly developed antihypertensive drugs should ideally not interfere with the patients' quality of life including sexual function. This study examined the effects of losartan, a nonpeptide, specific antagonist for type I angiotensin II receptors, on the male sexual behavior of rats. Spontaneously hypertensive rats (SHRs) and normotensive Wistar-Kyoto (WKY) rats were treated with losartan 30 mg/kg/day or saline control for 7, 30 and 90 days. Dark-cycle video recording was used to analyze the male sexual activities of the rats. No significant alteration in male sexual performance was observed after 7 and 30 days of treatment with losartan. In contrast, SHRs treated with propranolol 5 mg/kg/day showed increases in intromission latency, ejaculation latency and postejaculatory period indicating decreased libido and erectile and ejaculatory function. Upon completion of 90 days of losartan administration, the mount latency of the SHR was significantly increased, suggesting a decrease in libido although other parameters were unchanged and there was no effect in WKY rats. It is therefore concluded that losartan may have an advantage in preservation of sexual function when used clinically for the treatment of hypertensive disorders.

Original languageEnglish
Pages (from-to)132-139
Number of pages8
JournalPharmacology
Volume58
Issue number3
DOIs
Publication statusPublished - Mar 1999

Fingerprint

Losartan
Sexual Behavior
Libido
Inbred SHR Rats
Ejaculation
Inbred WKY Rats
Antihypertensive Agents
Orgasm
Video Recording
Angiotensin Receptor Antagonists
Diuretics
Propranolol
Quality of Life
Therapeutics

Keywords

  • Angiotensin II
  • Hypertension
  • Impotence
  • Losartan
  • Sexual function

ASJC Scopus subject areas

  • Pharmacology

Cite this

Effects of losartan on the sexual behavior of male rats. / Chan, Paul; Liu, Ju Chi; Tong, Yat Ching; Chen, Yi Jen; Wang, Chia Chen; Tomlinson, Brian; Cheng, Juei Tang.

In: Pharmacology, Vol. 58, No. 3, 03.1999, p. 132-139.

Research output: Contribution to journalArticle

Chan, P, Liu, JC, Tong, YC, Chen, YJ, Wang, CC, Tomlinson, B & Cheng, JT 1999, 'Effects of losartan on the sexual behavior of male rats', Pharmacology, vol. 58, no. 3, pp. 132-139. https://doi.org/10.1159/000028275
Chan, Paul ; Liu, Ju Chi ; Tong, Yat Ching ; Chen, Yi Jen ; Wang, Chia Chen ; Tomlinson, Brian ; Cheng, Juei Tang. / Effects of losartan on the sexual behavior of male rats. In: Pharmacology. 1999 ; Vol. 58, No. 3. pp. 132-139.
@article{3659b39dcaf1459b97f2a2f933b88cd1,
title = "Effects of losartan on the sexual behavior of male rats",
abstract = "Many commonly used antihypertensive drugs such as diuretics and beta-blockers can interfere with sexual function in both sexes, causing loss of libido, impairment of erectile function and ejaculation in men, and delay or prevent orgasm in women. Newly developed antihypertensive drugs should ideally not interfere with the patients' quality of life including sexual function. This study examined the effects of losartan, a nonpeptide, specific antagonist for type I angiotensin II receptors, on the male sexual behavior of rats. Spontaneously hypertensive rats (SHRs) and normotensive Wistar-Kyoto (WKY) rats were treated with losartan 30 mg/kg/day or saline control for 7, 30 and 90 days. Dark-cycle video recording was used to analyze the male sexual activities of the rats. No significant alteration in male sexual performance was observed after 7 and 30 days of treatment with losartan. In contrast, SHRs treated with propranolol 5 mg/kg/day showed increases in intromission latency, ejaculation latency and postejaculatory period indicating decreased libido and erectile and ejaculatory function. Upon completion of 90 days of losartan administration, the mount latency of the SHR was significantly increased, suggesting a decrease in libido although other parameters were unchanged and there was no effect in WKY rats. It is therefore concluded that losartan may have an advantage in preservation of sexual function when used clinically for the treatment of hypertensive disorders.",
keywords = "Angiotensin II, Hypertension, Impotence, Losartan, Sexual function",
author = "Paul Chan and Liu, {Ju Chi} and Tong, {Yat Ching} and Chen, {Yi Jen} and Wang, {Chia Chen} and Brian Tomlinson and Cheng, {Juei Tang}",
year = "1999",
month = "3",
doi = "10.1159/000028275",
language = "English",
volume = "58",
pages = "132--139",
journal = "Pharmacology",
issn = "0031-7012",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Effects of losartan on the sexual behavior of male rats

AU - Chan, Paul

AU - Liu, Ju Chi

AU - Tong, Yat Ching

AU - Chen, Yi Jen

AU - Wang, Chia Chen

AU - Tomlinson, Brian

AU - Cheng, Juei Tang

PY - 1999/3

Y1 - 1999/3

N2 - Many commonly used antihypertensive drugs such as diuretics and beta-blockers can interfere with sexual function in both sexes, causing loss of libido, impairment of erectile function and ejaculation in men, and delay or prevent orgasm in women. Newly developed antihypertensive drugs should ideally not interfere with the patients' quality of life including sexual function. This study examined the effects of losartan, a nonpeptide, specific antagonist for type I angiotensin II receptors, on the male sexual behavior of rats. Spontaneously hypertensive rats (SHRs) and normotensive Wistar-Kyoto (WKY) rats were treated with losartan 30 mg/kg/day or saline control for 7, 30 and 90 days. Dark-cycle video recording was used to analyze the male sexual activities of the rats. No significant alteration in male sexual performance was observed after 7 and 30 days of treatment with losartan. In contrast, SHRs treated with propranolol 5 mg/kg/day showed increases in intromission latency, ejaculation latency and postejaculatory period indicating decreased libido and erectile and ejaculatory function. Upon completion of 90 days of losartan administration, the mount latency of the SHR was significantly increased, suggesting a decrease in libido although other parameters were unchanged and there was no effect in WKY rats. It is therefore concluded that losartan may have an advantage in preservation of sexual function when used clinically for the treatment of hypertensive disorders.

AB - Many commonly used antihypertensive drugs such as diuretics and beta-blockers can interfere with sexual function in both sexes, causing loss of libido, impairment of erectile function and ejaculation in men, and delay or prevent orgasm in women. Newly developed antihypertensive drugs should ideally not interfere with the patients' quality of life including sexual function. This study examined the effects of losartan, a nonpeptide, specific antagonist for type I angiotensin II receptors, on the male sexual behavior of rats. Spontaneously hypertensive rats (SHRs) and normotensive Wistar-Kyoto (WKY) rats were treated with losartan 30 mg/kg/day or saline control for 7, 30 and 90 days. Dark-cycle video recording was used to analyze the male sexual activities of the rats. No significant alteration in male sexual performance was observed after 7 and 30 days of treatment with losartan. In contrast, SHRs treated with propranolol 5 mg/kg/day showed increases in intromission latency, ejaculation latency and postejaculatory period indicating decreased libido and erectile and ejaculatory function. Upon completion of 90 days of losartan administration, the mount latency of the SHR was significantly increased, suggesting a decrease in libido although other parameters were unchanged and there was no effect in WKY rats. It is therefore concluded that losartan may have an advantage in preservation of sexual function when used clinically for the treatment of hypertensive disorders.

KW - Angiotensin II

KW - Hypertension

KW - Impotence

KW - Losartan

KW - Sexual function

UR - http://www.scopus.com/inward/record.url?scp=0032898340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032898340&partnerID=8YFLogxK

U2 - 10.1159/000028275

DO - 10.1159/000028275

M3 - Article

C2 - 9925969

AN - SCOPUS:0032898340

VL - 58

SP - 132

EP - 139

JO - Pharmacology

JF - Pharmacology

SN - 0031-7012

IS - 3

ER -